|
OMER | Omeros Corp |
| Pharmaceutical Preparations |
| Book value per $ invested | $ -0.28 |
| Leverage | 218.72% |
| Market Cap | $ 793.4m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -120.8m |
| Margin | -35413.45% |
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and markets protein and small molecule therapies, and orphan indications targeting inflammation, complement-mediated diseases, central nervous system (CNS) disorders, and system-related diseases. immunological. The company is headquartered in Seattle, Washington.